We are a clinical-stage biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary Artificial Immune Modulation (AIM) nanotechnology platform, originally developed at Johns Hopkins University. Our AIM™ platform is the core of our innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted T cell response against a disease.
Our novel AIM™ platform utilizes nanoparticles to act as synthetic dendritic cells to identify and activate natural T cells with all of the key underlying attributes that are critical to fighting cancer and other immune-related diseases. Non-engineered T cells have the potential to provide meaningful clinical benefit for patients by mimicking natural immune response that reduces toxicities and enhances safety.
Our first product candidate, NEXI-001, for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) post-allogeneic transplant, is in Ph1/2 clinical trials.
Our innovative approach to immunotherapy is based on our proprietary AIM™ platform that uses nanoparticles to guide the immune system to direct a T cell response to fight disease.Learn More
Using our technology in cancer, we are developing therapies with T cells that target multiple tumor-relevant antigens.
Our proven executive team is supported by a board of directors comprised of renowned scientific thought leaders and seasoned biopharma executives.Learn More